• Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors...
    11 KB (951 words) - 07:29, 1 July 2024
  • to be a human polyclonal antibody (-pab) acting on the immune system. Olaratumab is an antineoplastic. Its name is composed of the components olara-t-u-mab...
    38 KB (3,088 words) - 05:02, 8 August 2024
  • Thumbnail for Insulin
    Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
    121 KB (13,799 words) - 17:37, 8 October 2024
  • Thumbnail for Dexamethasone
    Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
    68 KB (5,999 words) - 20:41, 31 August 2024
  • Ohtuvayre Ojemda Ojjaara olaflur (INN) olanzapine (INN) olaquindox (INN) olaratumab (USAN) oleandomycin (INN) Oleptro (Angelini-Labopharm) oletimol (INN)...
    7 KB (371 words) - 23:59, 30 September 2024
  • Thumbnail for Testosterone
    Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
    149 KB (15,717 words) - 11:49, 6 October 2024
  • Thumbnail for Amitriptyline
    Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
    93 KB (8,729 words) - 21:31, 30 September 2024
  • Thumbnail for Erythropoietin
    Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
    31 KB (3,430 words) - 05:24, 28 August 2024
  • Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
    13 KB (1,177 words) - 02:19, 4 September 2024
  • soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab Olaratumab Oportuzumab monatox Pembrolizumab Polatuzumab vedotin Prolgolimab Ramucirumab...
    12 KB (808 words) - 05:25, 15 September 2024